Among the 17 pretreatment plasma samples, we detected ctDNA in ten, twelve, and fifteen samples when profiling MP/KRAS, MP/FNA, and MP/TR, respectively, indicating an increased sensitivity of cancer detection by analyzing cfDNA across broad genomic target regions. The gene discussed is KRAS; the disease is cancer.